Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy

Biomarkers that are able to predict the response to omalizumab (OMA) in chronic spontaneous urticaria (CSU) are highly valued. The aim of our study was to evaluate the UAS7 (urticaria activity score assessed for 7 days), DLQI (dermatology life quality index), SII (systemic immune-inflammation index)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarkowski, Bartłomiej, Ławniczak, Julia, Tomaszewska, Katarzyna, Kurowski, Marcin, Zalewska-Janowska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095242/
https://www.ncbi.nlm.nih.gov/pubmed/37048721
http://dx.doi.org/10.3390/jcm12072639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095242/
https://www.ncbi.nlm.nih.gov/pubmed/37048721
http://dx.doi.org/10.3390/jcm12072639

Ejemplares similares